|
1. Biologie
|
|
|
Trouble with CRISPR? Maybe, But Maybe Not [In the Pipeline]
|
|
|
|
|
|
So
there are a number of reasons to wonder if these results are real. If
they are, other questions arise about the newer Cas9 variant enzymes and
various sgRNA designs, but I’m not even going to think about those, to
be honest, until this result has been replicated and given a thorough
going-over.
|
|
|
|
|
|
|
|
|
2. Etiologie
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
As Big Cancer Trials Ramp Up, Grail Goes Global, Merges With Cirina [Xconomy]
|
|
|
|
|
|
If
Grail were to successfully screen seemingly healthy people for signs of
cancer, it could be a major breakthrough. But that practice is
controversial; unnecessary biopsies and other medical procedures for
people who are wrongly diagnosed or whose cancer might never have spread
can also hasten health problems.
|
|
|
|
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
5. Traitements
|
|
|
|
Technique pinpoints the ‘partners in crime’ of cancer genes [Stanford Medicine]
|
|
|
|
|
|
The
researchers tackled 12 different types of cancers and over 3,000
cancer-associated mutations to identify thousands of new genetic
partnerships that could be amenable to drug treatment. In particular,
they found that 17 of the 89 potential synthetic lethal partners for a
well-known, leukemia-associated mutation are likely to be susceptible to
drugs that are either already clinically available or are under
development.
|
|
|
|
|
|
|
5.12 Immunothérapies
|
|
|
|
5.2 Pharma
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
|
Bicycle Therapeutics Maps Course to Clinic Backed by $52M Investment [Xconomy]
|
|
|
|
|
|
One
of the problems with cancer drugs is their broad effect: Besides
killing cancer cells, they also harm healthy tissue. Bicycle
Therapeutics is developing a new class of drugs that it says can offer a
more targeted approach, and it has raised $52 million to support plans
to bring its lead drug into clinical trials.
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
NICE backs Keytruda for first and second-line use [Pharma Times]
|
|
|
|
|
|
A
final appraisal determination issued by the Institute is now
recommending use of Keytruda (pembrolizumab) within the Cancer Drugs
Fund (CDF) as an option for untreated PD-L1-positive metastatic
non-small-cell lung cancer (NSCLC) in adults, following an initial
rejection earlier this year.
|
|
|
|
|
|
|
5.5.1.1 ASCO (général) - Industriels
|
|
|
AstraZeneca’s ASCO pledge? Be a better social media citizen [FiercePharma]
|
|
|
|
|
|
AstraZeneca
laid out five points for its new social tactics, including a promise to
stop tweeting paid advertising during the conference. The company said
it also plans to talk less and listen more, highlight important voices
other than its own, be sensitive to the serious nature of cancer and
work to simplify complex science.
|
|
|
|
|
|
|
5.5.10 ASCO (hémato)
|
|
|
|
5.5.4 ASCO (immunothérapies)
|
|
|
|
|
5.6 ESMO
|
|
|
|
6. Lutte contre les cancers
|
|
|
ESMO Welcomes the Adoption of the 2017 WHO Cancer Resolution [ESMO]
|
|
|
|
|
|
The
2017 WHO Cancer Resolution calls for national cancer control plans,
high quality cancer registries, increased cancer research, use of
clinical practice guidelines, timely access to medicines, medical
devices and palliative care, as well as a well-trained oncology
workforce.
|
|
|
|
|
|
|
6.6 Publications
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
6.9 Controverses
|
|
|